Findings seen in participants who previously failed two to four classes of oral preventive migraine medications
Amubarvimab Plus Romlusevimab Safe, Effective for COVID-19
Reduces risk for hospitalizations and/or deaths for nonhospitalized patients at high risk for clinical progression
Oral Fluvoxamine Plus Budesonide Cuts Severe Disease in COVID-19
Reduction in incidence of severe disease requiring advanced care seen among high-risk outpatients with COVID-19
Anakinra Does Not Prevent Mechanical Ventilation in Severe COVID-19 Pneumonia
However, authors say anakinra may have a role as early treatment for patients with less severe COVID-19
Early mAb Treatment Beneficial for Outpatients With COVID-19
Reduced risk of hospitalization or death seen at 28 days; lower risk seen for all individual mAb products
CDC: 2016 to 2021 Saw Increase in Adults Receiving Stimulant Prescriptions
During 2020 to 2021, more than 10 percent increase seen in percentage of women aged 15 to 44 years, men aged 25 to 44 years with prescription fills
Nirmatrelvir Cuts Risk for Post-COVID-19 Condition
Findings seen regardless of vaccination status and history of prior infection
FDA Advisers Back Full Approval of Paxlovid
Panel of FDA advisers says the medication remains safe and effective for high-risk patients
Viral, Symptom Rebound Common After COVID-19 Infection
Incidence of symptom rebound was higher in the nirmatrelvir plus ritonavir treatment group
Feds Will Start Limiting Telehealth Prescriptions for Painkillers, ADHD Drugs
Patients will be required to see a doctor in person to get a first prescription for opioids, ADHD drugs